[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551421":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":11,"centralContacts":31,"locations":40,"responsibleParty":133,"collaborators":11,"id":135,"slug":136,"hasResults":137,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":137,"sex":143,"minAge":144,"maxAge":11,"enrollmentInfo":145,"targetDuration":11,"studyType":148,"phases":149,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":57,"whyStopped":11,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},{"fullName":5,"class":6},"Akamis Bio","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NG-350A plus CRT during a 12-week active study treatment period","EXPERIMENTAL",null,[13,14,15],"Drug: NG-350A IV administration","Drug: Capecitabine oral administration","Radiation: Radiotherapy",[17,22,26],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":11},"DRUG","NG-350A IV administration","a tumour-selective anti-CD40-expressing adenoviral vector",[9],{"type":18,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"Capecitabine oral administration","chemotherapy",[9],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"RADIATION","Radiotherapy","long-course intensity-modulated radiotherapy",[9],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Vice President Head of Clinical Operations","CONTACT","+1 (484) 362-8918","robert.maietta@akamisbio.com",{"name":38,"role":34,"phone":11,"phoneExt":11,"email":39},"https:\u002F\u002Fwww.FortressStudy.org","oliver.rosen@akamisbio.com",[41,55,70,83,96,109,122],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":11},"University of Southern California","ACTIVE_NOT_RECRUITING","Los Angeles","California","90033","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-118.24368,34.05223,{"lat":53,"lon":52},{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":47,"countryCode":48,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"AdventHealth Orlando","RECRUITING","Orlando","Florida","32804",{"type":50,"coordinates":62},[63,64],-81.37924,28.53834,{"lat":64,"lon":63},[67],{"name":68,"role":69,"phone":11,"phoneExt":11,"email":11},"Mohamedtaki Tejani","PRINCIPAL_INVESTIGATOR",{"facility":71,"status":57,"city":72,"state":73,"zip":74,"country":47,"countryCode":48,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Washington University School of Medicine","St Louis","Missouri","63110",{"type":50,"coordinates":76},[77,78],-90.19789,38.62727,{"lat":78,"lon":77},[81],{"name":82,"role":69,"phone":11,"phoneExt":11,"email":11},"Moh'd Khushman",{"facility":84,"status":57,"city":85,"state":86,"zip":87,"country":47,"countryCode":48,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Ohio State University Comprehensive Cancer Center","Columbus","Ohio","43210",{"type":50,"coordinates":89},[90,91],-82.99879,39.96118,{"lat":91,"lon":90},[94],{"name":95,"role":69,"phone":11,"phoneExt":11,"email":11},"Eric Miller",{"facility":97,"status":57,"city":98,"state":99,"zip":100,"country":47,"countryCode":48,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"The University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":50,"coordinates":102},[103,104],-95.36327,29.76328,{"lat":104,"lon":103},[107],{"name":108,"role":69,"phone":11,"phoneExt":11,"email":11},"Sonal Noticewala",{"facility":110,"status":57,"city":111,"state":11,"zip":11,"country":112,"countryCode":113,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"University College London NHS FT","London","United Kingdom","UK",{"type":50,"coordinates":115},[116,117],-0.12574,51.50853,{"lat":117,"lon":116},[120],{"name":121,"role":69,"phone":11,"phoneExt":11,"email":11},"Maria Hawkins",{"facility":123,"status":57,"city":124,"state":11,"zip":11,"country":112,"countryCode":113,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"The Royal Marsden NHS Foundation Trust","Sutton",{"type":50,"coordinates":126},[127,128],-0.2,51.35,{"lat":128,"lon":127},[131],{"name":132,"role":69,"phone":11,"phoneExt":11,"email":11},"Sheela Rao",{"type":134,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100551421","phase-1-ng-350a-plus-chemoradiotherapy-for-locally-advanced-rectal-cancer-100551421",false,"NCT06459869","NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","A Multicentre, Open-label, Non-randomized, Phase 1b Trial of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Chemoradiotherapy in Locally Advanced Rectal Cancer (FORTRESS)","FORTRESS","Selected Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma of the rectum.\n* Locally advanced disease (clinical stage II-III based on pelvic MRI) selected by a multidisciplinary team for treatment with neoadjuvant CRT (which may be followed by CNCT to comprise planned TNT). Patients with oligometastatic disease are permitted provided that the site-specific multidisciplinary team deems them suitable for radical treatment\u002Fchemoradiation.\n* Confirmed microsatellite stable (MSS)\u002Fproficient mismatch repair (pMMR) status.\n* Provide written informed consent to participate.\n* ECOG Performance Status 0 or 1.\n* Must not be pregnant or breastfeeding.\n* Patients who are sexually active (with either sex) must agree to comply with contraceptive requirements.\n* Adequate lung reserve, renal function, hepatic function, and bone marrow\u002Fhematological function assessed ≤ 10 days prior to first dose.\n\nSelected Exclusion Criteria:\n\n* Recurrent rectal cancer.\n* Distant metastatic disease not amenable to radical treatment\u002Fchemoradiation.\n* Other prior malignancy active within the previous 3 years, except for local or organ confined early-stage cancer that has been definitively treated with curative intent, does not require ongoing treatment, has no evidence of residual disease, and has a negligible risk of recurrence and is therefore unlikely to interfere with the primary and secondary endpoints of the trial, including response rate and safety.\n* Splenectomy (patients with prior partial resection remain eligible if the Investigator considers splenic function to not be significantly compromised).\n* Active autoimmune disease that has required systemic therapy in the past 2 years, immunocompromised status in the opinion of the Investigator, or current treatment with systemic immunosuppressive therapy (daily prednisone equivalent for chronic system replacement not to exceed 10mg per day).\n* Infectious or inflammatory bowel disease in the 3 months before the first dose of study treatment.\n* Any clinically significant cardiovascular, peripheral vascular, cerebrovascular, or thromboembolic event in the last 1 month before the first dose of study treatment.\n* Major surgery in the 14 days before the first dose of study treatment or any surgical wounds that are not fully healed and free of infection or dehiscence.\n* Any prior surgery for rectal cancer or pelvic radiotherapy.\n* Any other anti-cancer or experimental therapy within the previous 12 months or that is planned during the active study treatment period.\n* Treatment with any other enadenotucirev-based virus (parent virus or transgene-modified variants), or anti-CD40 antibody at any time.\n* History of prior Grade 3-4 acute kidney injury or other clinically significant renal impairment.\n* Any ongoing Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 coagulation abnormality\u002Fcoagulopathy.\n\nURL:\n\nhttps:\u002F\u002Fwww.FortressStudy.org","ALL","18 Years",{"count":146,"type":147},30,"ESTIMATED","INTERVENTIONAL",[150],"PHASE1","The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence.",[153],"Locally Advanced Rectal Cancer (LARC)",[155,156],"Treatment naive","Oligometastatic","2026-06-10",{"date":159,"type":160},"2026-06-12","ACTUAL",{"date":162,"type":160},"2025-04-07",{"date":164,"type":147},"2028-12-30",{"name":5,"class":6},7]